Teva slides on 2Q results, guidance and dividend cuts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) plummeted $7.50 (24%) to $23.75 Thursday after reporting lower than expected 2Q17 earnings, cutting its dividend and announcing details of a restructuring plan.

Teva reported 2Q17 non-GAAP EPS of $1.02 on revenues of $5.69 billion. The Street was expecting an EPS of $1.06 on $5.72 billion...